Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.
about
The interplay between the microbiome and the adaptive immune response in cancer developmentInfectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective TherapyClinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)Molecular Pathogenesis of MALT LymphomaThe role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients.The microbiome and cancer.Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.Ocular Adnexal Lymphoma Presenting with Visual Loss.A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphomaIncidence of orbital, conjunctival and lacrimal gland malignant tumors in USA from Surveillance, Epidemiology and End Results, 1973-2009Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.Clinical aspects of malt lymphomas.Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML).Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.Low Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-cell Lymphoma.Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa.Microbiota: a key orchestrator of cancer therapy.Mitochondrial ribosomes in cancer.The etiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections.Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis.Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe.Orbital and ocular adnexal Mucosa-Associated Lymphoid Tissue (MALT) lymphomas: a single-center 10-year experience.Primary ocular adnexal lymphomas: a retrospective study of 25 patients.[Clarithromycin for monotherapy of B-cell MALT lymphoma?].Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot StudyDiagnostic Workup of Small B Cell Lymphomas: A Laboratory Perspective
P2860
Q26745703-517FF4C0-40BC-4E1A-940C-1BEF0AA52127Q26770344-4F201DD2-F1D0-4BB3-9123-AAA03392B5E1Q26771654-59AA48B4-CC44-4D90-971A-8A1CFBAE5836Q26825394-7998B0A8-3DF8-469D-94CC-3E01CCDED24AQ30299948-6C9117B7-2F4A-4C14-8BBB-4EF3541DFA6BQ33982223-9060A2D2-103A-4A21-A928-38F2CC7AB1A8Q35019302-0C72E86E-8786-4FCD-90EB-A19D17B13DA7Q36074644-F23EE258-4F2E-4C68-AE27-2722973B6728Q36667623-7AB96C36-B75B-4D06-8004-EC762FCDF022Q37038505-E4949812-3C55-4877-9BC1-71FA8C9D9E5FQ37500541-90C22316-66C6-4065-9939-0E3273B54AA6Q38138170-5163DBF2-F433-4DE0-B0D7-1E8CB482616AQ38252813-9B2D8256-0745-4818-BBBF-8FEB5DFD16F1Q38366528-F3DD9EAB-4107-4D53-BD26-A9A0A0482658Q38544142-935E26E0-40BA-488F-8C0E-9CFD6EF180D8Q38723880-16F0A417-4572-4E23-A8A1-5CE8A3F8B796Q38842920-D1307690-2308-4D1B-95F8-B8E52EBB559FQ39183428-5F109EBF-8F58-457D-970B-0E6E7D3325DCQ39264654-5B76CB1B-DBEA-410D-81E9-BEF33F1844BBQ40056500-CFB1878B-2AB9-4097-93BD-BD472A68D7A0Q40134895-4DA423F6-FF53-4FEF-B6B7-0C05A967DDCFQ40308641-A70DD85B-6E3C-4E97-8CD8-6534B3D94388Q41691477-12F7B163-A7CD-4F6A-B352-C89AA5CC3E25Q42234991-0E3F1B3C-6569-4959-A777-5ACBA2A1DE3CQ43738468-57431585-2CEA-45E2-9274-A3428034257BQ43807672-560E0C5D-406E-4669-8EF8-00EEA150C72CQ45713985-CC588A7D-D5F2-4CB1-827B-D07043FE8EE5Q47119181-597AE84E-511A-4409-A5FC-54134BBF1382Q52599792-A7E37BAD-554C-4090-98E3-8192E6041788Q58569832-48E57EF7-090D-456B-90E7-33325296C470Q58698933-C72F476B-7B50-451E-BED3-F96BADE8D9DE
P2860
Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chlamydophila psittaci eradica ...... international phase II trial.
@en
Chlamydophila psittaci eradica ...... international phase II trial.
@nl
type
label
Chlamydophila psittaci eradica ...... international phase II trial.
@en
Chlamydophila psittaci eradica ...... international phase II trial.
@nl
prefLabel
Chlamydophila psittaci eradica ...... international phase II trial.
@en
Chlamydophila psittaci eradica ...... international phase II trial.
@nl
P2093
P50
P356
P1476
Chlamydophila psittaci eradica ...... n international phase II trial
@en
P2093
Andrés J M Ferreri
Antonio Giordano Resti
Carlos Montalbán
Caterina Stelitano
Elisa Pasini
Franco Cavalli
Maria Elena Cabrera
Maurilio Ponzoni
Silvia Govi
Silvia Mappa
P304
P356
10.1200/JCO.2011.41.4466
P407
P577
2012-07-16T00:00:00Z